Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients

Pharmacokinetics Clinical Trial

Official title:

Open Label, Phase I Study to Assess and Compare the Pharmacokinetic Parameters After Single Oral Administration of Elafibranor 120 mg in Renal Impaired Patients and Healthy Subjects With Normal Renal Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03844555
• Other study ID #: GFT505-118-13
• Secondary ID: 2018-002481-39
• Status: Completed
• Phase: Phase 1
• Start date: February 28, 2019
• Est. completion date: March 21, 2020

Study information

• Verified date: August 2020
• Source: Genfit
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being conducted in order to assess the need for dose adjustment for elafibranor in participants with renal impairment. Pharmacokinetic parameters of elafibranor and its active metabolite (GFT1007) will be compared in severe renal impaired participants (eGFR<15mL/mn/1.73m^2) versus healthy participants after a single oral administration of elafibranor 120 mg

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: March 21, 2020
• Est. primary completion date: March 15, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

For all participants

1. Male or female subjects, aged 18 to 75 years inclusive;

2. Females participating in this study must be of non-childbearing potential or using highly efficient contraception for the full duration of the study

3. Negative serum pregnancy test at screening (if applicable);

4. Non-smoker subject or smoker of not more than 5 cigarettes a day;

For Renally Impaired Participants

5. ESRD patient not yet on dialysis with an estimated glomerular filtration rate (eGFR) <15mL/min/1.73m^2;

6. Documented renal impairment indicated by reduced eGFR within 12 months of screening or longer;

7. Stable renal function as evidenced by = 30 percent difference in two evaluation of eGFR on two separate occasions separated by at least 28 days with one measurement being the value at screening;

8. Body Mass Index (BMI) between 20 and 36 kg/m^2 inclusive.

For Healthy Volunteers with normal renal function:

9. eGFR = 90mL/min/1.73m^2;

10. No proteinuria (< 0.15 g/L determined by urinalysis);

11. Body Mass Index between 20 and 30 kg/m^2 inclusive and body weight not lower than 55kg;

12. Matched to at least 1 renal impaired patient by ethnic group, sex, age (+/- 10 years) and BMI (+/- 20 percent).

Other protocol-defined inclusion criteria may apply

Exclusion Criteria:

All Participants

1. Positive Hepatitis B surface antigen or anti Hepatitis C Virus antibody, or positive results for Human Immunodeficiency Virus 1 or 2 tests;

2. History or presence of drug or alcohol abuse (alcohol consumption > 40 grams/day);

3. Blood donation (including in the frame of a clinical trial) within 2 months before administration or blood donation planned during the study or within 2 months following participation to the study;

4. Participants who are pregnant or breastfeeding. Participants should not be enrolled if they plan to become pregnant during the time of study participation;

5. Positive results of screening for drugs of abuse;

6. Evidence or history of clinically significant uncontrolled hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, metabolic, systemic, infectious, or allergic disease (including drug hypersensitivity or allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing);

7. General anesthesia within 3 months before administration;

8. Major surgery within 28 days prior to randomization or major surgery planned during the next 6 months.

For Renally Impaired Participants:

9. History of renal transplant;

10. Evidence of an unstable clinically important medical condition other than impaired renal function;

11. Acute exacerbation or unstable renal function, as indicated by worsening of clinical and/or laboratory signs of renal impairment, within the 4 weeks before study drug administration;

12. Participants undergoing any method of dialysis or hemofiltration;

13. Disorders or surgery of the gastrointestinal tract which may interfere with drug absorption or may otherwise influence the pharmacokinetics of the investigational medicinal product (e.g., inflammatory bowel disease, resections of the small or large intestine, etc.);

14. History of febrile illness within 5 days prior to dosing;

15. Evidence of clinically significant liver disease or liver damage (e.g., hepatitis B or C, autoimmune hepatitis, primary biliary cirrhosis, non-alcoholic fatty liver disease, elevated aspartate aminotransferase or alanine aminotransferase that is considered clinically significant by the Investigator, etc.). Presence or history of protein drug hypersensitivity, or allergic disease diagnosed and treated by a physician

16. Any drug intake during the 2 weeks or 5 half-life of the drug preceding the first administration except those defined in the protocol

For Healthy Volunteers with normal renal function:

17. Any history or presence of renal disease

18. Frequent headaches (> twice a month) and / or migraines, recurrent nausea and / or vomiting;

19. Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease in Systolic Blood Pressure (=20 mmHg) or Diastolic Blood Pressure (=10 mmHg) within three minutes when changing from the supine to the standing position;

20. Inability to abstain from intensive muscular effort;

21. Any drug intake (except paracetamol 3g/d or contraception) during the 2 weeks or 5 half-life of the drug preceding the first administration;

22. Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study.

Other protocol-defined exclusion criteria may apply

Related Conditions & MeSH terms

• Kidney Diseases
• Pharmacokinetics
• Renal Impairment
• Renal Insufficiency

Intervention

Drug:
• Elafibranor
120mg oral single dose

Locations

Country	Name	City	State
France	Eurofins Optimed	Gières
Romania	ARENSIA Exploratory Medicine Unit, Nephrology Hospital Dr. Carol Davilla	Bucharest

Sponsors (1)

Lead Sponsor	Collaborator
Genfit

Countries where clinical trial is conducted

France,  Romania, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under curve from dosing time to last measurement (AUC(0-t)) of elafibranor and active metabolite	In participants with end stage renal disease compared to healthy volunteers	pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose
Primary	Area under curve from dosing time to infinity (AUC(0-8)) of elafibranor and active metabolite	In participants with end stage renal disease compared to healthy volunteers	pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose
Secondary	Plasma pharmacokinetics: maximum plasma drug concentration (Cmax)	for elafibranor and metabolites	pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose
Secondary	Plasma pharmacokinetics: elimination half-life (t1/2)	for elafibranor and metabolites	pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose
Secondary	Plasma pharmacokinetics: apparent volume of distribution (Vd/F)	for elafibranor	pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose
Secondary	Plasma pharmacokinetics: renal clearance (CLr)	for elafibranor and metabolites	pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose
Secondary	Plasma pharmacokinetics: apparent non renal clearance (CLnr/F)	for elafibranor	pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose
Secondary	Plasma pharmacokinetics: apparent total clearance (CL/F)	for elafibranor	pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose
Secondary	Plasma pharmacokinetics: area under the plasma concentration-time curve extrapolated from time t to infinity as a percentage of total area under the plasma concentration-time curve (%AUCextra)	for elafibranor and metabolites	pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose
Secondary	Plasma pharmacokinetics: area under curve from dosing time to last measurement (AUC(0-t)) of glucuronide metabolites and corresponding aglycones	for the glucuronide metabolites of elafibranor and corresponding aglycones	pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose
Secondary	Plasma pharmacokinetics: area under curve from dosing time to infinity (AUC(0-8)) of glucuronide metabolites and corresponding aglycones	for the glucuronide metabolites of elafibranor and corresponding aglycones	pre-dose and at 0.17, 0.33, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192 and 216 hours post-dose
Secondary	Urine pharmacokinetics: amount excreted (Ae)	for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose	pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose
Secondary	Urine pharmacokinetics: cumulative amount excreted (Ae0-t)	for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose	pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose
Secondary	Urine pharmacokinetics: percentage of dose excreted (Fe)	for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose	pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose
Secondary	Urine pharmacokinetics: cumulative percent of dose excreted (Fe0-t)	for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose	pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose
Secondary	Urine pharmacokinetics: renal clearance (CLR)	for elafibranor and metabolites, if applicable. 24 hours urine collection from dosing to 216 hours post-dose	pre-dose and then 24, 48, 72, 96, 120, 144, 168, 192, 216 hours post-dose